Taken together, these studies show frequencies of RECQL loss of function variants of 0–2.6% in patients with high-risk familial breast cancer who have previously tested negative for mutations in BRCA1/BRCA2 and other hereditary breast cancer genes. This evidence concerns the gene BRCA1 and breast cancer.